Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 11/06/25
Neumora Therapeutics, Inc. (NMRA) Discusses NMRA-215 Preclinical Results and Portfolio Updates, Including Obesity and Alzheimer's Disease Programs TranscriptSeeking Alpha • 10/27/25
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898GlobeNewsWire • 10/27/25
Neumora Therapeutics Announces Class-Leading Weight Loss Demonstrated with NMRA-215 in Preclinical Diet-Induced Obesity ModelGlobeNewsWire • 10/27/25
Neumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 08/06/25
Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025GlobeNewsWire • 07/23/25
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861GlobeNewsWire • 07/09/25
Kuehn Law Encourages Investors of Neumora Therapeutics, Inc. to Contact Law FirmGlobeNewsWire • 05/28/25
Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 05/12/25
Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025GlobeNewsWire • 04/28/25
NMRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Bronstein, Gewirtz & Grossman, LLC Investors with Losses Have Opportunity to Lead Class Action Lawsuit!Accesswire • 04/08/25
Levi & Korsinsky Notifies Shareholders of Neumora Therapeutics, Inc.(NMRA) of a Class Action Lawsuit and an Upcoming DeadlineAccesswire • 04/07/25
NMRA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Neumora Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitGlobeNewsWire • 04/07/25
Neumora Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. April 7, 2025 Deadline to file Lead Plaintiff Motion.GlobeNewsWire • 04/07/25
NMRA LAWSUIT ALERT: Levi & Korsinsky Notifies Neumora Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineAccesswire • 04/07/25
Neumora Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Neumora Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025 – NMRAGlobeNewsWire • 04/07/25
NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law FirmBusiness Wire • 04/07/25
Investors Who Lost Money on Neumora Therapeutics, Inc. (NMRA) Should Contact Levi & Korsinsky about Pending Class Action - NMRAAccesswire • 04/07/25
FINAL REMINDER NMRA DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Neumora Therapeutics, Inc. Investors to Participate in the Class Action LawsuitAccesswire • 04/07/25